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=Abstract  -Although the synthesis and metabolism of lipoprotein(a) [Lp(a)] are 
not clearly understood, the liver is considered to  be the main site of Lp(a) 
synthesis. We measured the serum concentration of Lp(a) and of other lipid 
parameters in 153 patients with various liver diseases( l0 chronic or  toxic 
hepatitis, 76 liver cirrhosis and 67 primary liver cancer). The serum Lp(a) was 
significantly decreased or even undetectable in liver diseases compared with the 
normal control group and the decrease of Lp(a) was more remarkable than the 
other lipid parameters. But there were no significant differences between the 3 
groups of liver diseases. Thus we suggest the possibility of Lp(a) measurement as 
a novel, sensitive parameter assessing dysfunction of the liver, regardless of 
dyslipidemic condition. 
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INTRODUCTION 
Lipoprotein(a) [Lp(a)] is an LDL-like particle 
with a large glycoprotein called apo(a) attached 
to its apo B moiety through disulfide bond (Eaton 
et a/. 1987;Mclean et a/. 1987). Many case- 
control studies have shown that plasma Lp(a) 
levels are associated with premature coronary 
heart disease (Rhoads et a/. 1986; Utermann 
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1989; Kostner et a/. 1981 ; Kim et a/. 1992) and 
thrombotic diseases (Scott 1989; Miles et a/. 
1989) because of its atherogenic as well as 
thrombogenic properties. 
The main site of the synthesis of Lp(a) is the 
liver (Tomlinson et a/. 1989; Rainwater et a/. 
1989; Kraft et a/. 1989). Thus the rate of its 
synthesis is believed to be regulated not only by 
genetic composition (Utermann et a/. 1987; Kim 
1992) but also by the functioning liver. So we 
measured serum cholesterol, triglyceride and 
HDL-cholesterol in various groups of liver 
diseases to evaluate changes caused by liver 
dysfunction. 
MATERIALS AND METHODS RESULTS 
Patients and cont ro l  groups. Patients 
included in this study were 100 males and 53 
females, aged between 35 and 65 years (mean 
age 50). They were clinically diagnosed with 
various liver diseases, consisting of 10 toxic or 
chronic active hepatitis, 76 liver cirrhosis(LC) 
and 67 primary liver cancer(PLCA). Values for 
control individuals were taken from previously 
studied data, Kim JQ et a1.(1991) for serum Lp 
(a) and Choi KH et a1.(1990) for other lipid 
parameters. Blood samples of both control 
groups were obtained from apparently healthy 
subjects who had no significant physical and 
laboratory abnormalities on routine check. 
Deter m i nat i on  o f  Lp (a).  Serum Lp(a) 
concentration was measured by an enzyme- 
l inked immunosorbent assay using a 
commercially available kit (Immuno AG, Vienna, 
Austria). The detection limit was 1.0 mg/dL. 
De te rmina t ion  o f  o ther  l i p i d  para-  
meters. Serum total cholesterol, triglyceride 
and HDL-cholesterol were assayed in a standard 
clinical laboratory. Blood samples were drawn 
after a 14 hour fast. Sera were separated within 2 
hours by low speed centrifugation and stored at 
-70°C until assay. Total cholesterol and 
triglyceride were measured by a cholesterol 
oxidase enzymatic method and a glycerol 
oxidase enzymatic method, respectively. Both 
assays were performed with a Hitachi 736-40 
chemistry analyzer(Hitachi, Ltd. Tokyo, Japan). 
HDL-cholesterol was measured by dextran 
sulfate-MgCI, precipitation method. 
Stat is t ica l  Analysis.  Data analysis was 
performed with the Statistical Analysis System 
(SAS). The difference between control group and 
all patients in serum Lp(a) level was examined 
by Student t-test and differences between liver 
disease groups were examined by the 1 way 
ANOVA test respectively. 
Frequency distributions of serum Lp(a)  
concentrations of controls and patients with liver 
diseases are shown in Fig. 1 .  Mean serum 
concentrat ion of Lp(a)  and other l ip id  
parameters in patients with liver diseases are 
l isted in Table 1 .  Mean serum Lp(a )  
concentration of patients was 4.5 mg/dL, which 
is significantly lower than that of the control 
group, 14.9 mgldL(p < 0.001 by Student t-test). 
Mean Lp(a) concentration in the hepatitis group 
was 2.2 mg/dL, in the liver cirrhosis group, 4.7 
mg/dL and in the primary liver cancer group, 4.6 
mg/dL. The differences in Lp(a) levels between 
the patients with liver diseases and control 
groups were more remarkable than those of 
conventional l ip id parameters such as 
cholesterol, triglyceride and HDL-cholesterol 
(Fig. 2) .  But the differences in Lp(a) levels 
between the 3 groups with liver diseases are 
statistically insignificant (p=.6188by 1 way 
ANOVA test). 
DISCUSS l ON 
It was the major goal of this study to 
investigate the influence of liver damage on the 
serum concentration of Lp(a). It is well-known 
that the serum concentration of apolipoprotein 
(a), the unique protein of Lp(a), is genetically 
controlled to a major degree and not modified by 
age, sex, and changes in diet, life style, or 
therapy with most lipid-lowering drugs except 
nicotinic acid (Fless et a/. 1984; Carlson et a/. 
1989; Kim et a/. 1991). Our result also revealed 
that the serum Lp(a) concentrations were not 
affected by age, sex and life style both in control 
and liver disease groups. The presence of apo 
(a )  mRNA in human, baboon,  and rhesus 
monkey liver and in the Hep G2 cell line is 
proven (Rainwater et a/. 1988). In individuals 
undergoing therapeutic liver transplantation, it 
was found that a complete conversion of the apo 
(a) phenotype of the recipient to that of the donor 
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Table 1. Mean concentrations of serum Lp(a) and other lipid parameters In the control group and in patients with 
Control Hepat~t~s LC PLCA All Pat~ents 
(n = 10) (n = 76) (n = 67) (n = 153) 
- - - -- - - - -- - - - -- - - -- - - -- -- 
Lp(a)* (mean + 2SD) 14.9 k 12.9a 2.2 i 1.4 4.7 + 8.5 4.6 + 7.1 4.5 1 7.6 
Total cholesterol 185.0b 129.7 103.5 118.8 11 7.3 
Triglyceride 129.6b 120.4 69.8 80.6 90.3 
HDL-cholesterol . 45.8b 29.1 25.3 24.2 26.2 
- - - - - - - - . -- - -- ~ p~ -- -- 
a Values taken from 250 subjects (Kim JQ eta/. 1991) 
b Values taken from 31 09 subjects (Choi KH et a/ ,  1990) 
* Lp(a) between the control group and all patients: p < 0.001 by Stuent t-test 
Lp(a) between the liver disease groups: p = 0.6188 by ANOVA test 
occurs after liver transplantation (Kraft et a/.  
1989). Thus the major site of synthesis of serum 
apo(a) appears to be the liver. Although apo(a) 
production in the testes and in the brain in 
rhesus monkeys has been reported (Tomlinson 
et a/. 1989), it is unlikely to indicate that these 
tissues are a site of active secretion. Marth et a/. 
(1982) reported that Lp(a) levels in heavy 
chronic ethanol drinkers are decreased due to 
modified liver function by ethanol. 
In our results, the serum concentration of Lp 
(a) is markedly decreased in patients with liver 
diseases. Although the skewed distribution of Lp 
(a) levels in the normal population is considered, 
the concentration of Lp(a) in liver diseases was 
significantly lower than that of the control group. 
Lp(a) level was less than 5 mg/dL in 80% of 
patients and about two thirds of all the patients 
showed an Lp(a) level which was near the 
detection limit of 1 mg/dL or even undetectable. 
These results are probably due to decreased 
synthesis of Lp(a) in the liver. But a follow-up 
study of Lp(a) levels in the patient group should 
b e  per formed.  It seems that there is no 
quantitative correlation between decrease of 
serum Lp(a) level and disease activity since the 
differences between each liver disease group 
were not significant. From in vivo turnover 
studies of Lp(a)  in humans, it has been 
concluded that differences in plasma Lp(a) 
concentrations among individuals are a result of 
di f ferences in synthesis rather than by 
differences in catabolism. The differences in Lp 
(a) levels between patients and control groups 
are more remarkable than those of other 
conventional lipid parameters and some patients 
in our study showed decreased Lp(a) level 
without any significant alterations in serum 
protein and transaminase level. 
In conclusion, the measurement of serum Lp 
(a) can be a sensitive method for assessing liver 
dysfunction 
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